ArticleMicroorganisms2020
Article in Microorganisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- The role ofFrontiers in medicine · 2025Pooled it
- Adjuvant Probiotics ofFrontiers in endocrinology · 2022Trial
- Gut-derived bacterial extracellular vesicles: the microbial dark matter contributing to host inflammation and cardiometabolic disease.Gut microbes · 2026Review
- A Review of Gut Microbiota Dynamics: From Healthy Gestation to Gestational Diabetes in Human and Mouse Models.Biomedicines · 2026Review
- Precision Microbiome Modulation: Exploring Lactobacillus spp. as A Targeted Strategy for Type 2 Diabetes Management.Current nutrition reports · 2026Review
- Longitudinal multiomics analysis of endocrine therapy effects and gut microbiota in breast cancer recurrence.Communications medicine · 2026Article
- Role of Gut Microbiota in Diabetic HFpEF: Mechanisms and Therapeutic Implications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Gut-kidney axis modulation by viable and inactivatedmSystems · 2025Article
- A critical role forActa pharmaceutica Sinica. B · 2025Article
- Review
- Understanding the complex function of gut microbiota: its impact on the pathogenesis of obesity and beyond: a comprehensive review.Diabetology & metabolic syndrome · 2024Review
- Detecting and quantifying Veillonella by real-time quantitative PCR and droplet digital PCR.Applied microbiology and biotechnology · 2024Article
- Insights into the Mechanisms of Action ofNutrients · 2024Review
- Intestinal Epithelial Axin1 Deficiency Protects Against Colitis via Altered Gut Microbiota.Engineering (Beijing, China) · 2024Article
- Review
- Article
- Article
- Milk protects against sarcopenic obesity due to increase in the genus Akkermansia in faeces of db/db mice.Journal of cachexia, sarcopenia and muscle · 2023Article
- A Higher Abundance ofMicroorganisms · 2023Article
- Role ofNutrients · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with refractory diabetes are defined as type 2 diabetes (T2D) patients; they cannot achieve optimal glycemic control and exhibit persistent elevations of hemoglobin A1c (HbA1c) ≥8% while on appropriate therapy. Hyperglycemia can lead to severe microvascular/macrovascular complications. However, in contrast to T2D, few studies have focused specifically on the gut microbiota in refractory diabetes. To examine this issue, we recruited 79 subjects with T2D and refractory diabetes (RT2D), and all subjects received standard therapy with Metformin or other hypoglycemic agents with or without insulin for at least one year. The α-diversity displayed no significant difference, whereas the β-diversity showed a marginal significance (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.